Cambrian Biopharma, a New York-based biotechnology company, raised $100M in Series C funding.
The round was led by Anthos Capital and SALT Fund with participation from Apeiron Investment Group, Future Ventures and Moore Capital. The company also announced the appointments of Paul Farr, Partner at Anthos Capital, and former Allergan CEO and BridgeBio director Brent Saunders to its board of directors.
The company intends to use the funds to develop therapeutics to combat the biological drivers of aging, treat and prevent age-related diseases and lengthen healthspan.
Led by James Peyer, CEO, and Christian Angermayer, Co-Founder and Chairman, Cambrian Biopharma is a longevity biotech company advancing multiple assets each targeting a biological driver of aging. The company’s approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life.
Cambrian operates as a Distributed Development Company (or DisCo) with a sourcing and development engine that enables the identification of science, deep due diligence, deployment of capital and teams of drug development experts all under the same model.
To date, Cambrian has 14 novel therapeutics in development across its majority-held pipeline companies.
With this financing, the company has raised approximately $160 million since the company was founded in 2019.